[1]Fengkui Zhang,et,al.Hetrombopag Added to Immunosuppressive Therapy in First-Line Treatment of Severe Aplastic Anemia: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial.2024 ASH.Abstract 304. [2]李燕娟, 等....
汇报时间:Sunday, December 8, 2024: 1:00 PM 汇报地点:Room 11 (San Diego Convention Center) 19 摘要号:663 标题:Decitabine Plus All-Trans Retinoic Acid Versus Decitabine Monotherapy for Myelodysplastic Syndromes with Excess ...
编者按:2024年12月7日~12月10日美国血液学年会(ASH)在美国圣地亚哥隆重举行,作为全球血液学领域规模最大、涵盖最全面的国际学术盛会之一,每年吸引着成千上万名来自世界各地的专家学者,分享最前沿的血液学进展和突破性临床数据。「医悦汇」分享入选的6项Late Breaking Abstract(LBA)以飨读者。 背景 遗传性和获得性红...
$传奇生物(LEGN)$$金斯瑞生物科技(01548)$美国东部时间2024年11月5日上午9点,2024年ASH年度大会的abstract就会在网上公开(如果是Late Breaking Abstract的话,那么会在2024年11月25日公开)。在本年度的会议上,Arcellx和吉利德合作开发的BCMA靶点CAR-T药物Anito-cel也会发布iMMagine-1二期临床数据(NCT05396885,4L或以...
编者按:2024年12月7日~12月10日美国血液学年会(ASH)在美国圣地亚哥隆重举行,作为全球血液学领域规模最大、涵盖最全面的国际学术盛会之一,每年吸引着成千上万名来自世界各地的专家学者,分享最前沿的血液学进展和突破性临床数据。「医悦汇」分享入选的6项Late Breaking Abstract(LBA),以飨读者。
December 7-10, 2024 会场/Venue: San Diego Convention Center, San Diego, CA, USA ASH Annual Meeting & Exposition——The premier event in malignant and non-malignant hematology 摘要征文投稿: KEY DATES-关键日期 Abstract Submission Site Opens/摘要提交开始 ...
If none of the abstract authors is an ASH member, the abstract must be sponsored by a current ASH member. ASH members are urged to use their best judgment in restricting sponsorship to a reasonable number of abstracts, keeping in mind that they are endorsing the authenticity and quality of ...
December 7-10, 2024 会场/Venue: San Diego Convention Center, San Diego, CA, USA ASH Annual Meeting & Exposition——The premier event in malignant and non-malignant hematology 摘要征文投稿: KEY DATES-关键日期 Abstract Submission Site Opens/摘要提交开始 ...
Conference abstractAbstract only Results of the Phase III Randomized Iskia Trial: Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone Vs Carfilzomib-Lenalidomide-Dexamethasone As Pre-Transplant Induction and Post-Transplant Consolidation in Newly Diagnosed Multiple Myeloma Patients Francesca Gay, Wilfried Roeloffze...
I’m going to go with the abstract presented by Nizar Jacques Bahlis, MD, bringing venetoclax [Venclexta] back into the forefront of multiple myeloma treatment.1 I had [often] overlooked venetoclax in patients with t(11;14) myeloma and just gone with mo...